Supplier
Amber Enterprises INC.
Amber Enterprises INC. was paid $2.35M by Medicaid between Jan 2018 and Nov 2024, across 14 billing codes. Its largest line is 90378, — 59% of everything it billed.
33Billing provider infoAMBER ENTERPRISES INC.
OMAHA, NE 68138
OMAHA, NE 68138
33aNPI1770586349assigned 05/27/2005
33bProvider typeDurable Medical Equipment & Medical Supplies
28Total paid$2.35M
24GClaims64,477
24DCodes billed14
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Durable Medical Equipment & Medical Supplies providers in Nebraska
Rank by total paid#5 of 89
Median peer was paid$129K
This provider vs. median18×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 16,156 | $220K | |
| 2019 | 13,170 | $617K | |
| 2020 | 10,596 | $1.13M | |
| 2021 | 7,035 | $108K | |
| 2022 | 6,883 | $111K | |
| 2023 | 7,009 | $123K | |
| 2024incomplete | 3,628 | $47K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 90378 | 59% | 575 | 452 | $1.39M | |
| J7518 | Mycophenolic acid, oral, 180 mg | 15% | 6,626 | 5,878 | $364K |
| J7503 | Tacrolimus, extended release, (envarsus xr), oral, 0.25 mg | 10% | 3,268 | 1,962 | $237K |
| J7507 | Tacrolimus, immediate release, oral, 1 mg | 5.3% | 10,818 | 8,212 | $125K |
| J7517 | Mycophenolate mofetil, oral, 250 mg | 2.9% | 4,419 | 3,662 | $68K |
| J7520 | Sirolimus, oral, 1 mg | 2.0% | 697 | 619 | $47K |
| Q0511 | Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period | 1.8% | 13,089 | 11,522 | $41K |
| Q0512 | Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period | 1.5% | 18,592 | 11,019 | $35K |
| J2315 | Injection, naltrexone, depot form, 1 mg | <1% | 35 | 26 | $23K |
| J7527 | Everolimus, oral, 0.25 mg | <1% | 65 | 38 | $9K |
| A4221 | Supplies for maintenance of non-insulin drug infusion catheter, per week (list drugs separately) | <1% | 589 | 512 | $3K |
| J7515 | Cyclosporine, oral, 25 mg | <1% | 172 | 156 | $3K |
2 more codes
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWILLIAMS, KRISTIN (PRESIDENT)
Parent organizationAMBER ACQUISITIONS LLC
| Provider | Location | Paid |
|---|---|---|
| Hyvacs, LLC | Omaha, NE | $1.12M |
| Amber Enterprises INC | Richardson, TX | $79K |
| Amber Enterprises INC | Ambler, PA | $2K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.